Ken is a general partner for HPV III at Hatteras Venture Partners and is involved in deal sourcing, investment decisions and implementing exit strategies. He is also a general partner for HVP II, where he has played an important role in deal sourcing, syndication and management recruitment, and evaluation. Ken is the former co-head of International Life Sciences for Ernst & Young, where he established a career over 29 years advising biotechnology and pharmaceutical companies throughout the world.
He got his start in biotech as part of the first audit team of Genentech in 1976. As co-founder and manager of the firm's national life sciences practice from his location in the San Francisco Bay Area, he advised numerous high profile life science companies with their initial public offerings, mergers and acquisitions, and strategic financings. Among others, these included: Affymax, Affymetrix, Applied ImmuneSciences, Chiron, Circadian, Genentech, Heartport, Systemix, ALZA, and Collagen.
Ken is a nationally-recognized financial matters expert and serves on the boards of Maxygen, Inc. (MAXY), Pozen, Inc. (POZN) and Inspire Pharmaceuticals, Inc. (ISPH), where he is Chairman of the Board. Until April 2009, Ken was also on the board of CV Therapeutics, which was acquired by Gilead Sciences, Inc.